Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > CYT997

CYT997

CYT997 structure

CYT997 

structure
  • CAS No:

    917111-44-5

  • Formula:

    C24H30N6O2

  • Chemical Name:

    CYT997

  • Synonyms:

    CYT997;N-Ethyl-N'-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea;CYT997 (Lexibulin);Lexibulin;1-ethyl-3-(2-methoxy-4-(5-methyl-4-((S)-1-(pyridin-3-yl)butylamino)pyrimidin-2-yl)phenyl)urea;CYT 997 N-Ethyl-N'-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea;N-Ethyl-N'-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea CYT997 (Lexibulin);Lexibulin(CYT-997)

  • Categories:

    Pharmaceutical Intermediates  >  Heterocyclic Compound

Description

Lexibulin(CYT-997) is a potent tubulin polymerisation inhibitor with IC50 of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo.IC50 value: 10-100 nM(cell assay) [1]Target: tubulin polymerisation inhibitor in vitro: CYT997 prevented the in vitro polymerization of tubulin with an IC50 of ~3 μmol/L (compared with the half-maximal inhibitory concentration of 2 μmol/L for colchicine under identical conditions) as determined using the c


1-ethyl-3-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea is a member of ureas.|Lexibulin is an orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. Lexibulin inhibits tubulin polymerization in tumor blood vessel endothelial cells and tumor cells, blocking the formation of the mitotic spindle and leading to cell cycle arrest at the G2/M phase; this may result in disruption of the tumor vasculature and tumor blood flow, and tumor cell death.

CYT997 Basic Attributes

434.55

434.243024

2GTU230HA1

DTXSID10238675

C77882

Characteristics

101

3.6

1.195

546.9±50.0°C at 760 mmHg

291.1±30.1 °C

1.610

Drug Information

CYT997

CYT997 Use and Manufacturing

N-Ethyl-N'-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2- yl)phenyl]urea Under a nitrogen atmosphere a mixture of 2-chloro-5-methyl-N-[(1S)-1-pyridin-3- ylbutyl] pyrimidin-4-amine (277 mg, 1.0 mmol) 4-{[(ethylamino) carbonyl] amino}-3- methoxyphenylboronic acid pinacol diester (416 mg, 1.3 mmol), tetrakis (triphenylphosphine) palladium (0) (116 mg, 0.1 mmol) in toluene-n-propanol (12 mL, 3: 1) was treated with 2M aqueous sodium carbonate solution (750 uL, 1.5 mmol). The resulting mixture was stirred vigorously whilst being heated at 100 °C for 17 hours. Once cool ethyl acetate (25 mL) was added and the mixture washed with Ha0 (6 x 15 mL), brine (20 mL) and dried (Na2SO4). Removal of solvent in vacuo then yielded crude product, which was purified by column chromatography using dichloromethane-methanol- aqueous ammonia (93: 7: 1) as eluent to furnish the product (110 mg, 57percent). lH-n. m. r. (CDCl3) 8 0.99 (t, 3H, /=7. 4 Hz, CH3), 1.18 (t, 3H, /= 7.2 Hz, CH3), 1.33-1. 60 (m, 2H, CH2), 1.82-2. 02 (m, 2H, CH2), 2.11 (s, 3H, Ar-Me), 3.25-3. 39 (m, 2H, CH2), 3.87 (s, 3H, OMe), 4. 80-4. 96 (m, 2H, 2 x NH), 5.26-5. 36 (m, 1H, CH), 6.98 (br s, 1H, Ar-NHCONH), 7.22-7. 28 (m, 1H, ArH), 7. 67-7.72 (m, 2H, ArH), 7.83-7. 88 (m, 1H, ArH), 8.05 (d, 1H, J = 0.8 Hz, ArH), 8.10 (d, 1H, J = 8.2 Hz, ArH), 8.47 (dd, 1H, J = 6. 6, 1. 8 Hz, ArH), 8. 69 (d, 1H, j= 2.0 Hz, ArH).N-Ethyl-N'-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2- yl)phenyl]urea Under a nitrogen atmosphere a mixture of 2-chloro-5-methyl-N-[(1S)-1-pyridin-3- ylbutyl] pyrimidin-4-amine (277 mg, 1.0 mmol) 4-{[(ethylamino) carbonyl] amino}-3- methoxyphenylboronic acid pinacol diester (416 mg, 1.3 mmol), tetrakis (triphenylphosphine) palladium (0) (116 mg, 0.1 mmol) in toluene-n-propanol (12 mL, 3: 1) was treated with 2M aqueous sodium carbonate solution (750 uL, 1.5 mmol). The resulting mixture was stirred vigorously whilst being heated at 100 °C for 17 hours. Once cool ethyl acetate (25 mL) was added and the mixture washed with Ha0 (6 x 15 mL), brine (20 mL) and dried (Na2SO4). Removal of solvent in vacuo then yielded crude product, which was purified by column chromatography using dichloromethane-methanol- aqueous ammonia (93: 7: 1) as eluent to furnish the product (110 mg, 57percent). lH-n. m. r. (CDCl3) 8 0.99 (t, 3H, /=7. 4 Hz, CH3), 1.18 (t, 3H, /= 7.2 Hz, CH3), 1.33-1. 60 (m, 2H, CH2), 1.82-2. 02 (m, 2H, CH2), 2.11 (s, 3H, Ar-Me), 3.25-3. 39 (m, 2H, CH2), 3.87 (s, 3H, OMe), 4. 80-4. 96 (m, 2H, 2 x NH), 5.26-5. 36 (m, 1H, CH), 6.98 (br s, 1H, Ar-NHCONH), 7.22-7. 28 (m, 1H, ArH), 7. 67-7.72 (m, 2H, ArH), 7.83-7. 88 (m, 1H, ArH), 8.05 (d, 1H, J = 0.8 Hz, ArH), 8.10 (d, 1H, J = 8.2 Hz, ArH), 8.47 (dd, 1H, J = 6. 6, 1. 8 Hz, ArH), 8. 69 (d, 1H, j= 2.0 Hz, ArH).

Computed Properties

Molecular Weight:434.5
XLogP3:3.6
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:9
Exact Mass:434.24302422
Monoisotopic Mass:434.24302422
Topological Polar Surface Area:101
Heavy Atom Count:32
Complexity:565
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.